A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
Berberine ursodeoxycholate has been studied for its serum lipid and lipoprotein lowering effects. Here the authors report an 18-week phase 2, randomised, double-blind, placebo-controlled clinical trial that tested the effect of berberine ursodeoxycholate in patients with fatty liver disease and diab...
Guardado en:
Autores principales: | Stephen A. Harrison, Nadege Gunn, Guy W. Neff, Anita Kohli, Liping Liu, Abbey Flyer, Lawrence Goldkind, Adrian M. Di Bisceglie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/13c7aeb937eb489ca602dac9be76c850 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis
por: Francisco Javier Rodal Canales, et al.
Publicado: (2021) -
Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
por: Alexander V. Smirnov, et al.
Publicado: (2021) -
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate.
por: Masaaki Hirayama, et al.
Publicado: (2021) -
Presumed Consent for Organ Donation: An Incoherent Justification
por: Formoso,Vicente, et al.
Publicado: (2021) -
Tear protein analysis in presumed congenital alacrima
por: Yaginuma S, et al.
Publicado: (2018)